Real-World Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)

Coleman et al. • 2026 • SGO

Read more

Relacorilant Plus Nab-Paclitaxel Demonstrates a Progression-Free Survival Benefit in Ovarian Cancer Independent of Tumor Glucocorticoid Receptor (GR) Expression Levels

Lorusso et al. • 2026 • SGO

Read more

Final Overall Survival Results from the Phase 3 ROSELLA Trial: Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023)

Lorusso et al. • The Lancet • Olawaiye et al. • SGO • 2026

Read more

Relacorilant + Nab-Paclitaxel vs Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer: Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Exposure-Response

Colombo et al. • 2026 • ESGO

Read more

ROSELLA: A Phase 3 Study of Relacorilant + Nab-Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023)

Lorusso et al. • 2026 • ESGO

Read more

Phase 3 ROSELLA (GOG-3073, ENGOT-ov72) Trial of Relacorilant + Nab-paclitaxel vs Nab-paclitaxel in Platinum-resistant Ovarian Cancer: Primary Results and Outcomes in Older Patients

Olawaiye et al. • 2025 • IGCS

Read more

ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + Nab-Paclitaxel in the Subgroup of Patients With Platinum-Resistant Ovarian Cancer (PROC) Previously Exposed to a PARP Inhibitor

Lorusso et al. • 2025 • ESMO

Read more

© 2026 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube